![]() |
市場調查報告書
商品編碼
1495421
治療診斷學市場:按產品、應用和最終用戶 - 2024-2030 年全球預測Theranostics Market by Product (Product, Services, Software), Application (Bone Metastatis, Cardiovascular Diseases, Lymphoma), End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年治療診斷學市場規模為23.3億美元,預計2024年將達26.7億美元,2030年將達61.8億美元,複合年成長率為14.89%。
治療診斷學代表了一個創新的醫學領域,它將診斷與基於診斷測試結果的標靶治療相結合。這種方法可以實現個人化治療,透過根據個人的疾病特徵量身定做治療,從而實現更有效率、更有效的醫療保健服務。治療診斷學的主要用途包括腫瘤學、心血管疾病、神經系統疾病和感染疾病。治療診斷學的最終用戶主要是醫院和診所、診斷實驗室和研究機構,它們可以透過整合治療和診斷過程來顯著改善患者護理。由於全球目標疾病的盛行率不斷增加,對治療診斷學的需求也不斷增加。個人化醫療的不斷成長趨勢和分子生物學的進步正在擴大治療診斷學的使用。此外,醫療保健基礎設施的成長和全球研發活動投資的增加是治療診斷學市場成長的主要驅動力。與研發相關的高成本、與資料隱私相關的問題以及個人化醫療的倫理考量對市場成長構成了重大挑戰。新生物標記、非侵入性成像技術和精準治療藥物的開拓預計將帶來市場成長機會。資料分析和機器學習的集合成為開發患者反應預測模型、最佳化治療方法和監測疾病進展提供了前沿。
主要市場統計 | |
---|---|
基準年[2023] | 23.3億美元 |
預測年份 [2024] | 26.7億美元 |
預測年份 [2030] | 61.8億美元 |
複合年成長率(%) | 14.89% |
區域洞察
美洲是治療診斷學市場開拓高度發展的地區,其特點是醫療保健支出高、專利註冊力度大以及對個人化醫療的大量投資。人們對個人化醫療益處的認知不斷提高,以及公共和私營部門對治療診斷學研究和應用的投資不斷增加,預計將在美洲建立市場基礎。在歐盟(EU),監管支持以及強大的醫療保健系統正在推動治療診斷學市場的成長。德國、法國和英國等國家處於前沿,其研究重點是癌症和神經退化性疾病。在醫療保健基礎設施投資以及與西方生物技術公司合作的推動下,中東地區重新表達了興趣。非洲在重點提供可及的診斷服務方面具有潛力,特別是在衛生系統發達的地區。在政府推動個人化醫療創新措施的推動下,亞太地區正迅速成為治療診斷學的關鍵地區。隨著日本人口老化,對先進治療診斷解決方案的需求日益成長,特別是在癌症和心血管疾病方面。隨著印度醫療保健產業的不斷發展以及對平價醫療的重視,對社區治療研究和合作研究的投資正在增加。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在治療診斷學市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對治療診斷學市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在治療診斷學市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[194 Pages Report] The Theranostics Market size was estimated at USD 2.33 billion in 2023 and expected to reach USD 2.67 billion in 2024, at a CAGR 14.89% to reach USD 6.18 billion by 2030.
Theranostics represents an innovative field in medical science that combines diagnostics with targeted therapy based on diagnostic test results. This approach enables personalized treatment, allowing for more efficient and effective healthcare delivery by tailoring treatment to the individual's specific disease characteristics. The primary applications of theranostics include oncology, cardiovascular diseases, neurological disorders, and infectious diseases, among others. The end-users of theranostics are largely hospitals and clinics, diagnostic laboratories, and research institutions, where the integration of therapeutic and diagnostic processes can significantly enhance patient care. The increasing prevalence of target diseases worldwide is expanding the need for theranostics. The growing inclination towards personalized medicines and rising advancements in molecular biology are expanding the usage of theranostics. Additionally, the growth of healthcare infrastructure and increasing investments in R&D activities globally serve as key drivers for the growth of the theranostics market. High costs associated with R&D and issues related to data privacy and the ethical considerations of personalized medicine pose significant challenges to market growth. Growing development of novel biomarkers, non-invasive imaging techniques, and precision therapeutics are expected to create opportunities for market growth. The integration of data analytics and machine learning presents a frontier for developing predictive models for patient response, optimizing treatment regimens, and monitoring disease progression.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.33 billion |
Estimated Year [2024] | USD 2.67 billion |
Forecast Year [2030] | USD 6.18 billion |
CAGR (%) | 14.89% |
Regional Insights
The Americas represents a highly developing landscape for theranostics market development, characterized by high healthcare expenditure, robust patent registrations, and significant investments in personalized medicine. Growing awareness of personalized healthcare benefits with rising public and private sector investments for research and application in theranostics are expected to create a platform for the market in the Americas. In the European Union (EU), regulatory support, along with strong healthcare systems, promotes the growth of the theranostics market. Countries including Germany, France, and the UK are at the forefront, with research centered on oncology and neurodegenerative diseases. The Middle East shows emerging interest, propelled by investments in healthcare infrastructure and partnerships with Western biotech firms. Africa displays potential particularly in regions with developing healthcare systems, focusing on accessible diagnostic services. Asia Pacific is rapidly emerging as a significant region in the theranostics field, backed by government initiatives aimed at boosting innovation in personalized medicine. Japan's aging population drives need for advanced theranostic solutions, particularly in oncology and cardiovascular diseases. India, with its growing healthcare sector and focus on affordable care, is witnessing increased investment in localized theranostic research and collaborations.
Market Insights
The market dynamics represent an ever-changing landscape of the Theranostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Theranostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Theranostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Clarity's Theranostic Prostate Cancer Trial Progresses at the Highest Dose Level Cohort
Clarity Pharmaceuticals announced the positive progression of its phase I/IIa SECuRE trial, evaluating the novel theranostic agent 64Cu/67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC) patients. In the latest update, the trial's cohort 3, operating under a 3+3 study design, treated three participants with the highest dose of 12GBq of 67Cu-SAR-bisPSMA, demonstrating promising safety and efficacy outcomes. This advancement, along with continued positive outcomes, particularly under the FDA's Expanded Access Program (EAP), underscores SAR-bisPSMA's promise to improve treatment outcomes for prostate cancer patients. [Published On: 2023-11-29]
BAMF Health and GE HealthCare Collaborate to Enable Sustainable and Scalable Solutions for Growth in Theranostics
GE Healthcare and BAMF Health have collaborated to accelerate the adoption of theranostic solutions across the U.S., emphasizing the importance of innovative technologies and services to enhance patient care. By integrating GE HealthCare's comprehensive solutions and BAMF Health's expertise in molecular imaging and theranostics, this partnership is poised to establish a robust framework for the deployment of precision medicine. [Published On: 2023-11-13]
UCLA Health to Open Theranostics Center
UCLA Health is gearing up to launch its pioneering outpatient theranostics center later this year, marking a significant milestone in the treatment of advanced cancer. This state-of-the-art 3,000-square-foot facility situated on the Westwood campus's 100 Medical Plaza building is designed to optimize patient care. With eight infusion chairs, the center aims to deliver up to 80 transfusions weekly, amounting to 4,000 treatment cycles annually, primarily focusing on patients with advanced prostate cancer, neuroendocrine tumors, and thyroid cancer. [Published On: 2023-05-22]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Theranostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Theranostics Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Ariceum Therapeutics GmbH, Astellas Pharma Inc., BAMF Health, Bayer AG, bioMerieux SA, Biosynth Ltd., Cardinal Health, Inc., Cerebral Therapeutics, Inc., Clarity Pharmaceuticals, Curasight A/S, Curium Inc., Evergreen Theragnostics, Inc., GE HealthCare Technologies, Inc., Hermes Medical Solutions AB, Icon Group, Indi Molecular, Inc., Integrated Clinical Oncology Network Pty Ltd., Invicro, LLC, Ipsen Pharma, Radiopharm Theranostics Limited, Ratio Therapeutics, Siemens Healthineers AG, SOFIE Co., Telix Pharmaceuticals Limited, and United Theranostics.
Market Segmentation & Coverage